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AbSTrACT
Objectives The analysis of annotated transcripts 
from genome- wide expression studies may help to 
understand the pathogenesis of complex diseases, such 
as systemic sclerosis (ssc). We performed a whole blood 
(WB) transcriptome analysis on rna collected in the 
context of the european PrecisesaDs project, aiming 
at characterising the pathways that differentiate ssc 
from controls and that are reproducible in geographically 
diverse populations.
Methods samples from 162 patients and 252 controls 
were collected in rna stabilisers. cases and controls 
were divided into a discovery (n=79+163; southern 
europe) and validation cohort (n=83+89; central- 
Western europe). rna sequencing was performed by 
an illumina assay. Functional annotations of reactome 
pathways were performed with the Functional analysis 
of individual Microarray expression (FaiMe) algorithm. 
in parallel, immunophenotyping of 28 circulating cell 
populations was performed. We tested the presence 
of differentially expressed genes/pathways and the 
correlation between absolute cell counts and rna 
transcripts/FaiMe scores in regression models. results 
significant in both populations were considered as 
replicated.
results overall, 15 224 genes and 1277 functional 
pathways were available; of these, 99 and 225 were 
significant in both sets. among replicated pathways, 
we found a deregulation in type- i interferon, Toll- like 
receptor cascade, tumour suppressor p53 protein 
function, platelet degranulation and activation. rna 
transcripts or FaiMe scores were jointly correlated with 
cell subtypes with strong geographical differences; 
neutrophils were the major determinant of gene 
expression in ssc- WB samples.
Conclusions We discovered a set of differentially 
expressed genes/pathways validated in two independent 
sets of patients with ssc, highlighting a number of 
deregulated processes that have relevance for the 
pathogenesis of autoimmunity and ssc.
InTrOduCTIOn
Systemic sclerosis (SSc) is a complex disease char-
acterised by immune system activation, widespread 
vasculopathy, fibrosis of the skin and internal 
organs.1 During the last decade, there has been a 
great advance in understanding the parthenogenesis 
of SSc2 with relevance in drug development and 
repurposing3 as well as in patient stratification and 
reclassification to pursue the goals of personalised 
medicine.4 A major contribution to the study of 
scleroderma pathogenesis has been given by next- 
generation sequencing (NGS) techniques.5–7
Gene expression profiling has long been used to 
understand the contribution of genes to biological 
functions and to discover deregulated pathways 
that may contribute to disease susceptibility.5 6 8 
The vast majority of gene expression studies in SSc 
are based on microarray technology, while NGS 
methods, namely RNA sequencing (RNA- seq), 
despite their advantages over existing approaches, 
have had limited applications.9–13 RNA- seq yields 
an unlimited potential due to its resolution and 
deep- coverage, low sensitivity to background noise, 
high sensitivity at the extremes of gene expres-
sion ranges, high accuracy and concordance with 
quantitative PCR as well as high reproducibility.14 
High- quality RNA can be extracted from whole 
blood (WB) samples collected with RNA stabi-
lisers, allowing the study of large populations15 
Key messages
What is already known about this subject?
 ► A coupled whole blood transcriptome and 
immunophenotyping analysis has never been 
performed in patients with systemic sclerosis.
What does this study add?
 ► Cell composition largely influences the 
transcriptome in a context- dependent and 
population- dependent manner.
 ► A set of validated transcripts and related 
pathways well differentiate cases from controls.
 ► Toll- like receptor signalling and other 
deregulated pathways underlie the 
pathogenesis of systemic sclerosis.
How might this impact on clinical practice or 
future developments?
 ► Results from Reactome pathway analysis may 
be helpful for drug repurposing.
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and reducing technical and source variability that may limit 
the reproducibility of results and introduce a systematic bias in 
multicentre studies.16
As a final step of transcriptome studies, differentially expressed 
(DE) genes are annotated to provide a biological interpretation of 
results.17 Usually, annotation is based on gene- set analysis failing 
to provide information at the personalised level. Novel strate-
gies developed to translate gene expression data into individual-
ised functional profiles proved more informative than gene- set 
enrichment analysis.18 19 The so- called Functional Analysis of 
Individual Microarray Expression (FAIME) algorithm18 exhibits 
more power compared with enrichment methods and yields 
reproducible results among different experiments pertaining to 
the same disease.20 FAIME is suitable for functional analysis in 
a multicohort that is characterised by a high background noise, 
ensuring the reproducibility of results in a discovery/validation 
setting.21
In the present study, we performed a genome- wide WB tran-
scriptome analysis of patients with SSc enrolled for the multi-
centre PRECISESADS project. Via a thorough bioinformatic 
pipeline, we discovered a reproducible set of DE pathways that 
withstand validation in geographically diverse populations. 
Finally, we show how the knowledge gained from our study can 
be used for drug repurposing and to find candidates of druggable 
pathways.
MATerIAl And MeTHOdS
Patients and controls
Patients with a diagnosis of SSc according to the American 
College of Rheumatology (ACR)/European League Against 
Rheumatism (EULAR) 2013 criteria22 participating in the multi-
centre PRECISESADS project23 were included. Patients were 
grouped according to their geographical origin into a discovery 
(Southern Europe: Italy, Portugal and Spain) and a validation 
(Central- Western Europe: Belgium, France, Germany, Hungary 
and Switzerland) set. Controls were selected for each set to 
match the cases according to age and gender. Patients were clas-
sified as diffuse cutaneous SSc (dcSSc) or limited cutaneous SSc 
(lcSSc); patients with definite SSc without fibrotic skin disease 
and puffy fingers were classified as lcSSc. All the patients and 
controls gave written informed consent for the study that was 
approved by local ethic committees.
rnA sequencing
Total RNA was extracted from samples collected in Tempus 
tubes using Tempus Spin technology (Applied Biosystems). 
Samples were depleted of alpha- globin and beta- globin mRNAs 
using globinCLEAR protocol (Ambion) and 1 µg of total RNA 
as input. Subsequently, 400 ng of globin- depleted total RNA was 
used for library synthesis with TruSeq Stranded mRNA HT kit 
(Illumina). Libraries were quantified using qualitative PCR with 
PerfeCTa NGS kit (Quanta Biosciences), and equimolar amounts 
of samples from the same 96- well plate were pooled. Four pools 
were clustered on a high output flow cell (two lanes per pool) 
using HiSeq SR Cluster kit V.4 and the cBot instrument (Illu-
mina). Subsequently, 50 cycles of single- read sequencing were 
performed on a HiSeq2500 instrument using and HiSeq SBS kit 
V.4 (Illumina). The clustering and sequencing steps were repeated 
for three runs to generate enough reads per sample. The raw 
sequencing data were preprocessed using bcl2fastq software and 
the quality assessed using FastQC tools.24 Cutadapt25 was used 
to remove 3′ end nucleotides below 20 Phred quality score and 
extraneous adapters; additionally, reads below 25 nucleotides 
after trimming were discarded. Reads were then processed and 
aligned to the UCSC Homo sapiens reference genome (Build 
hg19) using STAR V.2.5.2b.26 Two- pass mapping with default 
alignment parameters were used. To produce the quantification 
data, we used RSEM V.1.2.3127 resulting in gene level expres-
sion estimates (Transcripts Per Million, TPM and read counts). A 
sample would pass the RNA single QC if (1) the number of reads 
mapped to the genes was more than 7 million and (2) the RIN 
(RNA integrity number) value was higher than 7.
Immunophenotyping
Immunophenotyping was performed after blood collection 
in Duraclone tubes (Beckman Coulter) specifically designed 
and optimised for the PRECISESADS study. Harmonisation of 
instruments used for flow cytometry analysis was described else-
where, providing evidence of high- reproducible data in different 
centres.28 WB samples from patients and controls were collected 
in tubes with to ready- to- use unitised, dry format antibody 
cocktails and locally analysed within 24 hours. Flow cytometers 
were regularly (every 3 months) calibrated to obtain the same 
target mean fluorescence intensities of a reference instrument 
and whose coefficient of variation proved to be lower than 3.4% 
throughout the study.28 In addition, prior to the inclusion of any 
patient, a supplementary daily procedure was adopted to ensure 
that the deviation was below 5% for each sample.
data analysis
For RNA seq preprocessing and DE analysis, the Limma R 
package29 was used. For all the other analysis, custom codes 
written in python by LB were used; software and libraries used 
for the analysis are listed in the online supplementary material.
Differential expression analysis and validation
Data were first corrected for batch, age and sex effects with the 
voom method.30 DE analysis was performed retaining genes 
with a false- discovery rate (FDR)- corrected p value <0.05 and 
a fold- change (FC) between cases and controls FC|>1.5. DE 
analysis was independently performed in the discovery and vali-
dation sets and genes significant in both sets were considered as 
validated.
To evaluate to what extent genes selected by univariate feature 
selection in the discovery set jointly predicted the disease status 
in the validation set, a random forest model was built (500 trees) 
whose performance was evaluated via the area under precision- 
recall- gain curve (AUPRG)31 and via the area under receiver 
operating characteristic (AUROC).
Heatmaps were used to display validated genes: data were 
clustered by individuals’ similarity with the k- means algorithm 
and by transcript similarity, by means of the hierarchical clus-
tering Ward method.
Functional annotation, differential expression pathway analysis and 
validation
Individual functional annotations were performed with the 
FAIME algorithm18 considering Reactome pathways32 mapped 
by at least 10 genes/transcripts; Entrez Ids without official gene 
symbols were dropped from the analysis.
To allow the comparison of FAIME scores between datasets, 
values were normalised to the unit interval and cube root trans-
formation applied to unskew the data. Because FAIME scores 
are a composite measure of transcripts, FC cannot be used to 
measure the strength of pathway expression and the evaluation 
of effect size was used instead. Winsorised data were used to 
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Table 1 Demographic and clinical characteristics of patients with 
systemic sclerosis (SSc) in the discovery and validation cohort
Variable
discovery cohort 
(n=79)
Validation cohort 
(n=83)
Females, n (%) 72 (91.4%) 65 (78.3%)*
Age, years 56.6±13.7 58.5±13.9
Raynaud duration, years 15.8±11.2 12.5±9.9*
Disease duration, years 11±9.5 8.8±9.1
dcSSc, n (%) 13 (16.5%) 35 (50.7%)†
Autoantibodies, n (%)
ANA 76 (96.2%) 79 (95.8%)
ACA 37 (46.8%) 26 (31.3%)†
Anti- Topoisomerase- I 27 (34.2%) 41 (49.4%)†
ILD, n (%) 27 (34.2%) 44 (53%)†
FVC (% pred) 100.3±20.1 (1) 88.8±22.6† (2)
DLco (% pred) 69.6±19.4 (1) 55.1±17.4† (3)
PAH, n (%) 3 (4.3%) 4 (5.6%)
History of DU, n (%) 36 (52.9%) (4) 21 (25.3%)†
Telangectasia, n (%) 48 (61.5%) (5) 57 (68.7%)
Calcinosis, n (%) 24 (30.1%) (5) 13 (15.6%)†
Arthritis, n (%) 10 (12.8%) (5) 32 (38.6%)†
SRC, n (%) 1 (1.4%) (5) 0 (0%)
Myopathy, n (%) 2 (2.6%) (5) 1 (1.2%)
GORD, n (%) 47 (60.3%) (5) 52 (62.6%)
Intestinal_symptoms, n (%) 43 (54.4%) 31 (37.3%)*
Constipation 22 (28.2%) (5) 13 (15.6%)
Bloating 35 (44.9%) (5) 17 (20.5%)
Diarrhoea 18 (23.1%) (5) 15 (18.1%)
Abdominal pain 10 (12.6%) 13 (15.7%)
Weight loss, n (%) 4 (5.1%) (5) 14 (16.9%)*
Sicca syndrome, n (%) 26 (32.9%) 38 (46.3%)
Prednisone >5 mg/day, n (%) 10 (12.6%) 7 (8.4%)
Immunosuppressant, n (%) 16 (20.2%) 21 (25.3%)
MMF 2 (2.5%) 4 (4.8%)
MTX 2 (2.5%) 12 (14.5%)
LEF 1 (1.4%) 1 (1.2%)
AZA 6 (7.6%) 2 (2.4%)
CYC 2 (2.5%) 5 (6%)
Chronic iloprost, n (%) 36 (45.6%) 17 (20.5%)†
CCB, n (%) 55 (69.6%) 35 (42.2%)†
ASA, n (%) 49 (62%) 19 (23.9%)†
ACE- INH, n (%) 8 (10.3%) 15 (18.1%)
ERA, n (%) 15 (19%) 19 (22.9%)
PDE5, n (%) 2 (2.5%) 11 (13.3%)
Biologicals, n (%) 9 (11.3%) 0 (0%)
Abatacept 2 (2.5%) 0 (0%)
Tocilizumab 5 (6.3%) 0 (0%)
Anti- TNF 2 (2.5%) 0 (0%)
PGA 28.2±15.5 46.6±20.2†
Data from: (1) 64, (2) 82, (3) 79, (4) 54 and (5) 78 patients.
*p<0.05 versus discovery.
†p<0.01 versus discovery.
ACA, anticentromere antibodies; ACE- INH, ACE inhibitors; ANA, antinuclear 
antibodies; ASA, low- dose acetilsalycilc acid; AZA, azathioprine; CCB, calcium- 
channel blockers; CYC, cyclophosphamide; dcSSc, diffuse cutaneous SSc; DLco, 
diffusing capacity for carbon monoxide; DU, digital ulcers; ERA, endothelin receptor 
antagonists; FVC, forced vital capacity; GORD, gastro- oesophageal reflux disease 
confirmed by gastroscopy, manometry or X- rays; HCQ, hydroxycloroquine; ILD, 
interstitial lung disease; LEF, leflunomide; MMF, mycopheolate mophetil; MTX, 
methotrexate; PAH, pulmonary artery hypertension confirmed by right- heart 
catetherisation; PDE5, phosphodiesterase 5 inhibitors; PGA, physician's global 
assessment (0–100); SRC, scleroderma renal crisis; TNF, tumour necrosis factor.
calculate the robust effect size (dr)
33 and to perform t- test anal-
ysis. Annotations with a FDR p<0.05 and with a |dr|>0.62897, 
corresponding to a moderate effect size34 were considered as 
significant.
Random forest and heatmaps were used to evaluate the 
joint effect of functional annotations and to visualise their 
interactions.
Druggable functional annotations
Genes contributing to validated FAIME pathways were explored 
via the Drug Gene Interaction database (DGIdb).35 Functional 
annotations were considered as druggable if at least one gene/
annotation was found in the DGIdb. Relationship between drug-
gable annotations were explored via UpSet36 as described in the 
online supplementary material 1.
Association between gene expression and FAIME scores with 
immunophenotyping
Absolute cell counts were correlated with RNA transcripts and 
FAIME scores to quantify the contribution of immune cells to 
gene expression and function. We assumed that gene expression 
and functional annotations are a linear combination of expres-
sion levels of immunophenotyped cells as a function of their rela-
tive proportions.37 The elastic net regression method was applied 
to both sets in order to perform feature selection; L1 penalty 
was set to 1 (equivalent to least absolute shrinkage and selection 
operator) and the optimal regularisation parameters were chosen 
by internal fivefold cross- validation. Standardised β coefficients 
were used to determine the relative contribution ϕ of each of the 
19 cell subtypes to the model:  ϕ = βx/
∑19
i=1 βi, x = 1, 2, ..., 19 . 
Selected features were used to build regression models in each 
subset and tested for their generalizability in the other set. The 
overall internal and external contribution of linear models to 
transcripts or to functional annotation was expressed by means 
of the adjusted coefficient of determination (adjR2). The same 
procedure was performed including into the model the use of 
steroids (prednisone >5 mg/day, yes/no), hydroxychloroquine 
(yes/no) and immunosuppressants (any molecule, yes/no). The 
final model (with or without therapy as covariate) was chosen as 
the one that maximised the adjR2.
reSulTS
Overall, 162 patients with SSc and 252 controls were consid-
ered after quality check and filtering; of these, 79 cases aged 
56.6±13.7 years and 163 controls aged 53.8±11.8 years were 
included into the discovery set and 83 cases aged 58.5±13.9 
years and 89 controls aged 55.2±13.6 years were included in 
the validation set. Demographic and clinical characteristics of 
patients with SSc are reported in table 1.
differential expression analysis
A total of 15224 genes passed the quality control and were 
selected for the analysis; the average number of reads/sample 
was 13 695 621.25 (range 8 318 927–32 665 993). Of those, 
167 and 709 genes were significant in the discovery and vali-
dation sets, respectively; 99 genes overlapped between the two 
sets and were thus considered as replicated (online supple-
mentary file 1). Heatmap representation of replicated genes 
is shown in figure 1. Cases and controls were well separated 
after clustering analysis (χ2=143.202, p<0.001). The majority 
of genes were downregulated in SSc subjects that, conversely, 
consistently showed an increased expression of interferon 
(IFN)- related genes.
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Figure 1 Heatmap of validated genes. Heatmap representation of replicated genes in the discovery (purple) or validation (pink) sets. Patients (in 
red) and controls (in green) are clustered column- wise via the k- means algorithm, genes are clustered row- wise via the hierarchical clustering Ward 
method. Patient- wise data standardisation was applied before clustering.
RNA- seq transcripts in the random forest classification algo-
rithm could well discriminate cases from controls: with an 
AUROC=0.908 and AUPRG=0.851 after feature selection in 
the discovery set and replication in the validation set (figure 2, 
in comparison with Reactome pathways).
Pathway analysis
A total of 1277 unique Reactome pathways were selected. The 
dr of individualised FAIME scores and the number of FDR- 
corrected pathways was higher in the validation set than in 
the discovery set (online supplementary figure 1). Overall, 241 
individual pathways were different between cases and controls 
in the discovery set, 676 in the validation set and 225 in the 
intersection between the two sets (online supplementary file 
2). Validated FAIME pathways are represented in the heatmap 
in online supplementary figures 2 and 3, clustering analysis 
yielded a χ2=89.385, p<0.001 for the case versus control 
comparison.
Selected pathways in the discovery set could well predict 
the class in the validation set with an AUROC=0.914 and an 
AUPRG=0.884 (figure 2, in comparison with WB transcripts).
druggable functional annotations
Druggable Reactome pathways can be explored using UpSet, 
as shown in online supplementary figure 4. For illustrative 
purposes, we show an example where the existence of any drug 
associated with immune system activation/IFN signalling is eval-
uated. Two drugs, bortezomib and irinotecan, emerged as poten-
tial candidates to tackle the terms R- HSA-168256 (immune 
system), R- HSA-168249 (innate immune system), R- HSA-
168928 (DDX58/IFIH1- mediated induction of IFN- alpha/beta), 
R- HSA-913531 (IFN signalling) R- HSA-909733 (IFN alpha/beta 
signalling) and R- HSA-109581 (apoptosis).
The complete druggable pathways are included in the supple-
mental upset SSc\data\FAIME SSc folder (found within the online 
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Figure 2 Validation of non- linear classification models fit of the random forest algorithm. Differentially expressed genes or pathways in the 
discovery set are used to train the model, whose performance is evaluated in the validation set. The performance is evaluated via the area under (AU) 
receiver operating characteristic (ROC) or precision- recall gain (PRG) curves. Black lines: curves for models trained on transcriptome data; grey lines: 
curves for models trained on annotated pathways.
Table 2 Immunophenotyping results
Cell subset (gating strategy), count/mm3
discovery (n=203) Validation (n=144)
SSc (n=64) Ctrl (n=139) q SSc (n=72) Ctrl (n=72) q
Basophils (CD123 HLA- DR−) 58.3±39.7 184.9±464.6 0.009 44.3±30.6** 56±60.1* 0.211
Eosinophils (CD15+ CD16−) 174.5±371.1 167.3±174.8 NS 146.6±86.6 152.6±95 NS
Neutrophils (CD15− CD16+) 4116±2389 4363.3±2544.1 NS 4270±1648.8 3312.9±1324.3** 0.001
LDGs (CD15hi CD14−) 0±0.1 0±0.2 NS 0±0.1 0±0.1 NS
Classical monocytes (CD14hi CD16−) 376.9±170.3 390.4±220.8 NS 342.8±168.8 308.8±123.5** 0.208
Intermediate monocytes (CD14+/hi CD16+) 52.2±34.8 50.9±36.2 NS 65.3±37.2** 48.4±24.8 0.004
Non classical monocytes (CD14+ CD16 hi) 12.3±12.1 9.8±7.1 0.071 10.3±7.6 8.2±6.3 0.09
NK regulatory (CD3− CD56hi CD16−) 7±6.4 10±7.5 0.002 4±3.6*** 6.8±4.6*** 0.004
NK cytotoxic (CD3− CD56lo CD16hi) 132.7±95.3 234.2±200.9 1.18E-05 112.4±69.6 190.3±121.3 0.002
NK- like T cells (CD3+ CD56+) 65.7±54.9 130.9±119.3 1.18E-05 50.4±74.3** 101.7±85.1** 8.45E-05
B cells (CD3− CD19+) 152±109.9 256.3±217.6 1.43E-05 169.2±136.2 191.7±116.6** 0.212
CD4 T cells (CD3+ CD4+ CD8−) 649.9±284.3 1084.9±893.4 1.18E-05 607±316 760.8±329.7** 0.043
CD8 T cells (CD3+ CD4 CD8+) 258.6±144.8 408.9±279 2.11E-05 226.8±154.2 304.5±192.2** 0.044
Double positive T cells (CD3+ CD8+ CD4+) 11.4±9.5 23.1±23.1 5.76E-05 14.5±20.8 17.9±17.8 0.16
Double negative T cells (CD3+ CD8- CD4−) 20.7±14 42±33.7 1.11E-06 22.7±42.6 25±20.6*** 0.185
mDC1 (Lin- HLA- DR+ CD11c+ CD123 lo CD141− CD1c+) 2.6±3 11.3±37.8 0.005 1.2±1.1** 3±6.7** 8.12E-04
mDC2 (Lin- HLA- DR+ CD11c+ CD123 lo CD141+ CD1c−) 60.1±90.8 156±514.6 0.046 44.7±45.9 39.3±37.6** NS
mDC (Lin- HLA- DR+ CD11c +CD123 lo CD141− CD1c) 17.1±17.2 32.1±137.4 0.353 7.7±8.7* 10.9±29.9** NS
pDC (Lin- HLA- DR+ CD11c+ CD123 lo CD11c− CD123hi) 10.2±9.2 55.1±174.2 8.22E-04 4.8±4.9* 11.2±22.8*** 2.9E-05
False- discovery rate (FDR) corrected p values (q) after cube root transformation to unskew the data.
*q<0.05 versus discovery; **q<0.01 versus discovery; ***q<0.001 versus discovery.
DC, dendritic cells; LDG, low density grains; NK, natural killers.
supplementary material 2) that can be explored as described in 
the online supplementary material 1.
Correlations of gene expression and FAIMe scores with 
immunophenotyping
Flow cytometry data were available for 203 and 144 subjects in 
the discovery and validation sets (table 2). Cell counts of cases 
and controls within each set were different for many cell subsets; 
additionally, cases- to- cases or controls- to- controls differences 
could also be observed comparing the discovery and the valida-
tion sets.
Results from elastic net regression analysis are detailed in 
the online supplementary file 3. The influence of immuno-
phenotyping on RNA transcripts and functional annotation is 
summarised in table 3.
The number of regression models explaining at least 10% 
of the variance of transcripts/FAIME annotations after correc-
tion for concurrent therapy was higher in the validation than 
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Table 3 Influence of immunophenotyping cell composition on differentially expressed (DE) genes and pathways
de
discovery Validation
no Yes no Yes
RNA transcript adjR2<0.1 n 7208 18 5257 68
adjR2≥0.1 n 7917 81 9258 641
OR (CI95) 4.09 (2.46 to 6.83) 5.35 (4.16 to 6.89)
Median (IQR) 0.202 (0.146–0.261) 0.217 (0.153–0.298) 0.222 (0.165–0.291) 0.304 (0.219–0.396)
0.202 (0.146–0.262) 0.224 (0.167–0.296)
FAIME
Reactome pathway
adjR2<0.1 n 438 17 231 47
adjR2≥0.1 n 614 208 370 629
OR (CI95) 8.73 (5.24 to 14.53) 8.35 (5.95 to 11.73)
Median (IQR) 0.201 (0.149–0.268) 0.217 (0.161–0.294) 0.188 (0.146–0.25) 0.271 (0.206–0.344)
0.207 (0.153–0.276) 0.24 (0.171–0.316)
Correlation between absolute cell counts and RNA transcripts or FAIME scores in the discovery and validation sets after regression analysis and correction for concurrent therapy. 
The adjusted coefficient of determination (adjR2) of elastic net models is shown. ORs and 95% confidence intervals (CI95) are calculated for categorised values; the 10% of 
explained variance is chosen as threshold to categorise regression models (meaningful≥10%, not meaningful<10%). Significant DE genes or pathways are more likely to be 
discovered when the transcriptome or functional data correlate with immunophenotyping data.
DE, differentially expressed; FAIME, Functional Analysis of Individual Microarray Expression.
in the discovery set: RNA, discovery, 7998/15224 (52.5%)—
validation, 9899/15224 (65%); Reactome pathway, discovery 
822/1277 (64.4%)—validation, 999/1277 (78.2%). The median 
variance explained by meaningful regression models was also 
higher in the validation set than in the discovery set (22%–24% 
vs about 20%). Regression models limitedly predicted RNA 
transcripts or FAIME scores in independent populations and 
only 849/7730 (11%) and 89/802 (11.1%) of relevant RNA 
transcript or pathway models (adjR2>0.1) in the discovery 
population were replicated in the validation set. These results 
suggest that immunophenotype mostly influences RNA tran-
scriptome and the related functional annotations in a context- 
dependent and population- dependent manner. Differences in 
cell counts between cases and controls may influence the associ-
ation between meaningful regression models and DE transcripts 
or pathways (table 3). This association is more pronounced in 
the validation set as a likely consequence of a differential neutro-
phil count between cases and controls (online supplementary file 
3). Overall neutrophils accounted for 36% and 29.3% of the 
variance of transcripts and for 30.7% and 27% of the variance 
of functional annotations in the two sets. CD4+ and CD8+ T 
cells were the subsets that most contributed to transcripts/anno-
tations, while the average effect of steroids on functional path-
ways was no higher than 2.3% and 4.7% (online supplementary 
file 3).
The influence of Reactome pathways/therapies on cell subsets 
was exploratively analysed via elastic net models in the two 
pooled populations; results are reported in online supplemen-
tary file 5. Overall therapies only marginally influenced cell 
composition.
dISCuSSIOn
The present study is the first attempt to characterise the WB 
transcriptome in a large cohort of patients with SSc as part of an 
international multicentre collaborative project. The discovery/
validation strategy we applied guarantees that our results are 
reproducible and robust against environmental factors, genetic 
background and phenotypic variation ensuring their generalis-
ability.38 Indeed, the testing of findings in populations different 
in time, space and clinical characteristics provides an added 
inherent value compared with the simple replication in pheno-
typically similar populations, providing evidence for the causal 
relationship between genetic transcripts and disease.38
A larger number of DE genes were identified in the validation 
than in the discovery set (709 vs 167). This discrepancy seems 
mostly related to a different cell composition in the two popu-
lations (table 1). In particular, strong differences, both in cases 
and controls, were observed in the neutrophil cell count that 
after correlation analysis and correction for concurrent therapy 
emerged as the major determinant of RNA abundance (online 
supplementary file 3). Nonetheless, we cannot exclude that 
other factors may have contributed to these results, including 
genotype- specific characteristics or a different phenotype and 
severity of SSc subjects (online supplementary table 1). Attempts 
to elucidate the latter aspect performing subset analyses were 
not fully convincing due to the relatively low effect size, despite 
significant FDR- adjusted p values (online supplementary file 4) 
and hence we cannot draw any definite conclusion: both a loss 
of power due to a reduced sample size and a true lack of signifi-
cance can be advocated as explanation.
To gain biological insight on transcriptome data and to char-
acterise deregulated pathways, we performed a functional anal-
ysis via the FAIME framework. FAIME is advantageous in the 
context of a multicentre study because it is capable of dissecting 
the heterogeneity of complex diseases, avoiding normalisation 
and batch effect issues.21 We could thus confirm the pivotal 
role of IFN activation and signalling in SSc pathogenesis39 and 
highlighting the deregulation of several INF- related pathways. 
Figure 3 summarises the processes related to the TLR cascades 
that eventually contribute to IFN type I40 and inflammasome 
induction. These findings reinforce the notion that TLR and 
inflammasomes could constitute a potential target in SSc.41
Other pathways of interest are those related to the tumour 
suppressor p53 gene (TP53). p53 is an ubiquitous protein that 
regulates genes involved in DNA repair, stress response, cell 
growth arrest and metabolism, apoptosis and senescence, ulti-
mately inhibiting tumorigenesis.42 Point mutations of TP53 have 
been described in interstitial lung disease.43 The expression of 
p53 in fibroblasts isolated from IPF lungs is reduced compared 
with HC- derived fibroblasts,44 and in ex vivo experiments, the 
loss of p53 activity has been related to a fibrogenic phenotype 
and its restoration may have a role in the resolution of lung 
fibrosis. The deregulation of TP53 we observed in SSc (R- HSA-
5633007) as a consequence of translational (R- HSA-3700989, 
R- HSA-6806003) and post- translational processes (R- HSA-
6804758, R- HSA-6804760, R- HSA-6806003, R- HSA-6804757) 
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Figure 3 Toll- like receptor (TLR) pathways deregulated in systemic sclerosis (SSc). Representation of TLR pathways and downstream mediators 
following TLR4 activation. Deregulated Reactome pathwyas in SSc, either upregulated (in green) or downregulated (in red) according to the Functional 
Analysis of Individual Microarray Expression (FAIME) method. TLR pathways are consistently upregulated in SSc (top). Downstream deregulated 
pathways include Toll/IL-1 receptor (TIR) domain- adapter MyD88- related signalling; MyD88- independent signalling; TIR- domain- containing adapter- 
inducing interferon- beta (TRIF) signalling; interferon regulatory factor 3 (IRF3) activation following interaction of TRIF with noncanonical kinase TBK1; 
activation of the nuclear factor-κB (NF-κB) by the downstream mediators of MyD88, tumour necrosis factor receptor- associated factor 6 (TRAF6) or 
via the transforming growth factor (TGF)-β-activated kinase (TAK1); activation of the inflammasome by MyD88- dependent mechanisms; activation 
of the inflammasome NLRP3 (Cryopyrin); induction of apoptosis by inflammasomes; production of interleukin-1 (IL-1) by inflammasomes and IL-1 
signalling (R- HSA-9020702, R- HSA-446652); downregulation of the negative feedback pathway constituted by phosphoinositide 3- kinases (PI3K) and 
its downstream target serine serin/threonine kinase Akt (PKB) (R- HSA-109704).
may contribute to extracellular matrix remodelling (R- HSA-
1474244, R- HSA-1474228) and collagen turnover (R- HSA-
1442490 in both sets and R- HSA-1474290 in the discovery set). 
Similarly, the loss of p53 activity and reduced transcription of 
DNA repair genes (R- HSA-6796648) may partially explain the 
increased DNA damage described in SSc.45
Several other deregulated pathways were discovered by our 
analysis (online supplementary file 2), whose abnormalities are, 
in some cases, consistent with known pathogenetic mechanisms 
of SSc as summarised in online supplementary table.
Pathway analysis based on transcriptome data is potentially 
useful to discover putative therapeutic targets for drug repur-
posing. Herein, we describe a framework to find druggable 
pathways based on the curated database DGIdb35 and the UpSet 
visualisation tool.36 The combination of druggable pathways that 
can be explored is gargantuan and cannot be summarised, yet the 
illustrative example we provide shows the potentialities of our 
approach. Two drugs emerged as potential candidates to tackle 
immune system and IFN pathway: bortezomib and irinotecan. 
Bortezomib, a protease inhibitor, is currently under investigation 
in a phase II clinical trial.46 Irinotecan is an analogue of campto-
thecin (CPT),47 a topoisomerase I inhibitor capable of reducing 
collagen production in SSc fibroblasts.48
It could be argued that RNA- seq analysis of specific leucocyte 
subsets could theoretically have been more informative compared 
with WB analysis.49 50 Nonetheless, available methods for subset- 
specific expression profiling are ill- suited for large studies and 
the choice of the cell type to analyse is not obvious. Our correla-
tion analysis clearly shows that population- dependent effects are 
unavoidable and strategies to accommodate these differences 
still need to be developed. Based on our experience, coupling 
RNA sequencing and immunophenotyping could add a valuable 
information to transcriptome studies and such strategy is partic-
ularly advisable in WB- based approaches.
A potential drawback of our research is related to the average 
long- standing disease duration of enrolled patients and the lack 
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of a prospective evaluation. Caution should be exercised in trans-
lating our findings to early dcSSc subjects. Overall, our results 
are hardly comparable with findings from studies involving 
patients with low- disease duration, analysing other biosamples 
or relying on different analytical platforms (all reviewed in 
previous work8).
Summarising, we extensively describe modification of RNA 
transcripts and related annotations with functional, patho-
physiological and therapeutic implications. We show that these 
modifications are context and population dependent although 
reproducible across samples with different genetic background 
and phenotype. Further studies are, however, required to learn 
to what extent our findings can be translated in non- Caucasian 
populations.
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